Actelion settlement in US antitrust case over Tracleer gets final nod
MLex Summary: Actelion Pharmaceuticals’ $65 million settlement to resolve third-party payers’ claims accusing it of blocking market entry for a generic version of brand name drug Tracleer has been granted final...To view the full article, register now.
Already a subscriber? Click here to view full article